SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, ...
Belite Bio, Inc. announced positive developments regarding its lead drug candidate, Tinlarebant, for treating Stargardt disease (STGD1) and ongoing trials for geographic atrophy (GA). Following an ...
BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional ...
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...
LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing ...
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune ...
Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback